Plain-English translation of NCT06701825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new approach to giving , a medication that helps prevent the body from rejecting a transplanted kidney. Instead of using a one-size-fits-all dose, researchers want to see if personalizing the dose based on your genes works better and costs less money. Your body's genes affect how quickly you process this medication, and the study will check whether tailoring the dose to your genetics helps you stay healthier after your transplant.
After a kidney transplant, getting the right dose of is critical—too little and your body may reject the new kidney, too much and you may experience serious side effects. This study exists because genetic testing might help doctors find your perfect dose from the start, rather than guessing and adjusting over time.
You likely qualify if…
You likely don't qualify if…
After you join the study, you'll have genetic testing done to look at how your body processes . If the testing shows you have a genetic variation, you'll be randomly placed into one of two groups: one group will receive personalized dosing recommendations based on your genes, while the other group will receive standard dosing. You'll then be monitored at scheduled visits over the study period, with doctors checking how well the medication is working and whether you're having any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Spain